Beta-blockers in critical care and obstructive lung diseases: New directions

Research output: Chapter in Book/Report/Conference proceedingChapter


Beta-adrenergic blocking agents (i.e., β-blockers) are extensively used for myriad conditions, though their use in patients with critical illness is controversial. Concerns over their negative chronotropic, anti-hypertensive, and potential bronchospastic effects temper their use in sepsis, especially in patients with underlying obstructive lung diseases. Beta-blockers are commonly used in critically-ill patients with atrial arrhythmias, particularly atrial fibrillation, though guidelines supporting their use in such patients are lacking. Similarly, guidelines for β-blockers to combat the stimulant effects of sympathomimetic drugs such as amphetamines and cocaine are mainly based on expert opinion, and controversy exists as to which β-blocking agents are superior. This chapter will focus on the data surrounding the use of β-blockers in common illnesses seen in the intensive care unit and their effects on obstructive lung diseases.

Original languageEnglish (US)
Title of host publicationBeta-Blockers
Subtitle of host publicationPhysiological, Pharmacological and Therapeutic Implications
PublisherNova Science Publishers, Inc.
Number of pages28
ISBN (Electronic)9781536133127
ISBN (Print)9781536133110
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Beta-blockers in critical care and obstructive lung diseases: New directions'. Together they form a unique fingerprint.

Cite this